Agenix Licenses Tyrian Dx Technology to Develop Microarray Device | GenomeWeb

NEW YORK (GenomeWeb News) – Australian diagnostics and biopharmaceutical firm Agenix announced today it is licensing a rapid point-of-care diagnostic technology from Tyrian Diagnostics for development of a microarray device.

Agenix will use Tyrian's DiagnosticIQ platform for human applications. Bayer CropScience currently licenses the technology for agricultural applications.

Agenix is providing Tyrian A$500,000 (US$517,000) in shares of its stock to be paid in installments through June 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.